Chapter 6- Rejection of Tissue Transplant Flashcards
Process of Rejection
T cells and antibodies produced against graft antigens react against and destroy tissue graft
Where are major antigenic differences between the donor and the recipient?
HLA alleles
Characteristics of HLA genes
highly polymorphic
always some differences between individuals
Allografts
same species
Xenografts
grafts from one species to another
2 types of T-Cell Mediated Reactions
Acute cellular rejection, chronic rejection
When does Acute Cellular Rejection occur?
initial months after transplantation
Clinical signs of acute cellular rejection
organ failure
increased vascular permeability and local accumulation of mononuclear cells
What cells secrete cytokines during acute cellular rejection
activated CD4+ T cells
What occurs during chronic rejection
lymphocytes react against alloantigens in vessel wall
cytokines released to induce local inflammation
3 types of Antibody-Mediated Reactions
hyperacute, acute antibody-mediated, chronic antibody-mediated rejection
How does hyperacute antibody-mediated rejection occur?
preformed antidonor antibodies are present in circulation of recipient
Why would a recipient have preformed antidonor antibodies?
From previous transplant, prior blood transfusions, and multiparous women
How does acute antibody-mediated rejection occur?
Antidonor antibodies produced after transplantation
What is the initial target of antidonor antibodies in acute antibody-mediated rejection?
graft vasculature
How does chronic antibody-mediated rejection occur?
gradual development
affects vascular components
Methods of Increasing Graft Survival (5)
HLA matching Immunosuppressive therapy T cell and B cell depleting antibodies Pooled intravenous IgG Plasmapheresis
How does HLA matching increase graft survival in kidney transplants?
benefit if all polymorphic HLA alleles are matched
What organs is HLA matching not done?
liver, heart, lungs
What immunosuppressive therapies are used to increase graft survival?
steroids to reduce inflammation
mycophenolate mofetil to inhibit lymphocyte proliferation
Tacrolimus to inhibit T cell function
Risk of using immunosuppressive therapy
increased risk of infections
How does pooled intravenous IgG increase graft survival?
suppresses inflammation
When is plasmapheresis used?
severe antibody-mediated rejection
Polyoma virus
reactivates when a person is too immunosuppressed
infects renal tubules
Immunosuppression and Increased Latent Viruses
increased risk for re-activation of latent viruses
EBV-induced lymphomas
HPV
Kaposi sarcoma
What is a bone marrow transplant?
transplantation of hematopoietic stem cells
What is a HSC transplant used for? (3)
hematologic malignancies
bone marrow failure syndromes
inherited stem cell defects
Bone marrow failure syndrome
aplastic anemia
Inherited Stem Cell defects
sickle cell anemia
thalassemia
immunodeficiency states
Where do transplanted HSC cells come from? (2)
Peripheral blood after they are mobilized from bone marrow after given hematopoietic growth factors
Umbilical cord form newborn
How does the recipient allow transplanted stem cells to engraft?
recipient treated with high doses of chemotherapy to destroy immune system
When does Graft-vs-Host Disease occur?
transferred cells from donor recognize alloantigens in recipient and attack the host cells
When is GVHD most seen?
in HSC transplantation
When is GVHD rarely seen?
in transplantation of solid organs rich in lymphoid cells or transfusion of unirradiated blood
ex. liver
How to minimize GVHD
HLA-matching
When does acute GVHD occur?
within days/weeks/couple months after bone marrow transplantation
What clinical manifestations occur with GVHD? (4)
immune system, skin (rash), liver (jaundice), intestine (diarrhea)
What occurs during chronic GVHD? (4)
cutaneous injury, chronic liver disease, damage to GI tract, immune system devastated
Immune system in chronic GVHD
shrinking of thymus, depletion of lymphocytes in lymph nodes
recurrent and life-threatening infections
What mediates GVHD?
T lymphocytes in the transplanted donor cells
*depletion of T cells may eliminate GVHD
Risks for depleting T cells to help GVHD (3)
recurrent tumors in leukemic patients
increased graft failures
increased risk of EBV related B cell lymphoma